A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Ascending Doses of QLS12010 Capsules in Healthy Adult Participants
Latest Information Update: 06 May 2025
At a glance
- Drugs QLS 12010 (Primary)
- Indications Atopic dermatitis; Hidradenitis suppurativa; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 06 May 2025 New trial record